Our research group is led by Prof. Annalisa Santucci and is located within the University of Siena, Department of Biotechnology, Chemistry and Pharmacy. We are one of the three Academic members of the DevelopAKUre Consortium. We have great expertise in the study of proteins related to microorganisms (such as the pathogens Helicobacter pylori and Neisseria meningitidis, but also the well-known yeast Saccharomyces cerevisiae) and human diseases, including rare ones (gastric cancer, pancreatic cancer, osteosarcoma, osteoarthritis, Lesch-Nyhan syndrome and alkaptonuria, or AKU). In the last years, we developed specific biochemical, structural biology, bioinformatics, and proteomic/post-genomic skills and platforms for the study of AKU and we were able to provide novel insights into AKU physiopathology. Access to such molecular technologies are crucial to understand AKU and to evaluate the efficacy of therapeutic approaches. Research in AKU in Siena dates back 2008, thanks also to a collaboration with the University of Liverpool and a fruitful student exchange programme. Since then, Siena has emerged as the Italian centre for the study of AKU. This is due to joint efforts from us as scientists, investigating the disease at the molecular level, rheumatologists of Siena Hospital, and the Italian AKU patients Association, aimAKU. Besides our laboratory routine, we are also constantly committed to raising awareness of AKU and disseminating AKU related information. This means not only scientific publications and meetings, but also keeping in touch with doctors, patients and caregivers. Last September we held here in Siena the first Italian AKU meeting, which gathered together scientists, doctors and patients from different regions.
DevelopAKUre is a series of major international clinical trials, run by a consortium of 12 European partners. It aims to study a potential new drug, called nitisinone, and assess its potential effectiveness in treating the rare disease, alkaptonuria (AKU).
DevelopAKUre is co-funded by a grant from the European Commission. This website is run by a UK patient group, the AKU Society. Learn more about AKU on the AKU Society's What is AKU page.
In today’s blog Chief investigator Prof. Ranganath reinforces the need for SONIA 2 pat.. ...more